Research across Glaucoma
Related studies from across the Glaucoma family.
6 trials tracked for neovascular glaucoma: 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 15 citations.
Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Aflibercept has been evaluated in Phase 3 trials for the management of neovascular glaucoma. In one study, Aflibercept administration resulted in a significant reduction in intraocular pressure (IOP) from baseline to week 1 (-8.3; p=0.0004).
In another Phase 3 trial involving Aflibercept, results for IOP change at week 1 were -8.5 and -4.9 (p=0.0644). Regarding the Neovascularization of the Iris (NVI) grade, these trials reported improvement rates of 13% and 70.4% respectively.
Ranibizumab was also evaluated in a Phase 3 trial for this condition.
AI synthesis of 0 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
Related studies from across the Glaucoma family.